RPS6 Antibody

What is RPS6 and why is it significant in cellular research?

RPS6 (Ribosomal Protein S6) is a component of the 40S small ribosomal subunit that plays a critical role in controlling cell growth and proliferation through the selective translation of particular classes of mRNA. It is part of the small subunit (SSU) processome, the first precursor of the small eukaryotic ribosomal subunit. During assembly of the SSU processome in the nucleolus, RPS6 works with other ribosome biogenesis factors to generate RNA folding, modifications, rearrangements, and cleavage. Its phosphorylation status serves as an important indicator of mTOR pathway activity, making it a valuable target in research on translational control mechanisms .

What are the common alternative names for RPS6 in the literature?

When reviewing literature, researchers should be aware that RPS6 is also referred to by several other names including: 40S ribosomal protein S6, Small ribosomal subunit protein eS6, Phosphoprotein NP33, and OK/SW-cl.2. Understanding these alternative nomenclatures is essential for comprehensive literature searches and proper experimental design, particularly when comparing results across different studies and publications .

What is the molecular weight of RPS6 and how does this impact detection?

RPS6 has a calculated molecular weight of approximately 29 kDa, though the observed molecular weight in experimental conditions typically ranges from 29-32 kDa. This variation can be attributed to post-translational modifications, particularly phosphorylation. When designing Western blot experiments, it's important to use appropriate positive controls and molecular weight markers to accurately identify RPS6 bands. Researchers should be aware that the phosphorylated forms may migrate slightly differently than the non-phosphorylated form, which can affect band interpretation in experimental results .

What antigen retrieval methods are most effective for RPS6 detection in IHC applications?

For immunohistochemical detection of RPS6 in formalin-fixed, paraffin-embedded tissues, antigen retrieval is critical for optimal results. The recommended method is heat-induced epitope retrieval (HIER) using TE buffer at pH 9.0. Alternatively, citrate buffer at pH 6.0 can be used, though potentially with different sensitivity. The choice between these methods may depend on the specific tissue type and fixation conditions. Researchers should compare both methods on control tissues to determine which provides optimal staining with minimal background for their particular experimental system .

How can phospho-specific RPS6 antibodies be validated for specificity?

To validate phospho-specific RPS6 antibodies, peptide competition experiments are essential. In this approach, aliquots of the antibody are pre-incubated with: (1) the phosphopeptide immunogen used to raise the antibody, (2) the corresponding non-phosphopeptide, and (3) a generic phosphoserine-containing peptide. Following pre-incubation, each preparation is used in the detection method of choice (e.g., Western blotting). A truly specific phospho-RPS6 antibody will show signal blocking only when pre-incubated with the specific phosphopeptide immunogen, but not with the non-phosphopeptide or generic phosphopeptide. This validates that the antibody specifically recognizes the phosphorylated form of RPS6 at the site of interest, rather than just any phosphorylated serine residue or the non-phosphorylated protein .

What are the common causes of non-specific binding when using RPS6 antibodies?

Non-specific binding in RPS6 antibody applications can result from several factors. Insufficient blocking is a primary cause - ensure thorough blocking with appropriate agents (typically 5% BSA or non-fat milk). Excessive antibody concentration can also lead to non-specific binding; always titrate antibodies to determine optimal concentration. Cross-reactivity with similar epitopes in other proteins may occur, particularly with polyclonal antibodies. To troubleshoot, researchers should include appropriate negative controls (such as IgG isotype controls), consider using monoclonal antibodies for increased specificity, and validate results with multiple detection methods. Pre-absorbing antibodies with the immunizing peptide can also help confirm specificity of observed signals .

How can inconsistent RPS6 phosphorylation signals be addressed in experimental setups?

Inconsistent RPS6 phosphorylation signals often reflect the dynamic nature of this post-translational modification in response to cellular conditions. To address this variability, researchers should standardize cell culture conditions (serum concentration, confluence levels, and starvation protocols) prior to stimulation. The timing of sample collection is crucial as phosphorylation events can be transient. Include positive controls (e.g., cells treated with known activators of the mTOR pathway) and negative controls (e.g., cells treated with rapamycin or wortmannin, which inhibit the PI3K/mTOR pathway). It's also important to use phosphatase inhibitors in lysis buffers to prevent post-lysis dephosphorylation. When comparing samples across experiments, normalize phospho-RPS6 signals to total RPS6 levels rather than just to loading controls like actin or GAPDH .

What strategies can improve detection sensitivity when RPS6 expression is low?

When detecting low-abundance RPS6 or its phosphorylated forms, several approaches can enhance sensitivity. First, consider sample enrichment techniques such as immunoprecipitation prior to Western blotting. Signal amplification systems like biotin-streptavidin can significantly increase detection sensitivity. Enhanced chemiluminescence (ECL) substrates with extended signal duration allow for longer exposure times. For immunohistochemistry or immunofluorescence, tyramide signal amplification (TSA) can dramatically improve detection of low-abundance targets. Additionally, optimizing primary antibody incubation conditions (increasing incubation time to overnight at 4°C) and using highly sensitive detection systems (such as NorthernLights™ conjugated secondary antibodies for immunofluorescence) can substantially improve detection of low-level RPS6 expression .

How can RPS6 antibodies be employed to study mTOR signaling pathway dynamics?

RPS6 antibodies, particularly phospho-specific antibodies targeting serines 235/236 or 240/244, serve as powerful tools for investigating mTOR signaling dynamics. Researchers can use paired antibodies (total and phospho-specific) to quantify the relative phosphorylation state of RPS6 in response to various stimuli or inhibitors. This approach allows for temporal analysis of mTOR pathway activation following treatment with growth factors, amino acids, or pathway inhibitors like rapamycin. For single-cell analysis, phospho-RPS6 immunofluorescence can reveal cellular heterogeneity in mTOR activation within tissues. Multi-color flow cytometry using phospho-RPS6 antibodies enables quantitative analysis of mTOR activity across different cell populations. Additionally, proximity ligation assays (PLA) using RPS6 antibodies paired with antibodies against other mTOR pathway components can visualize protein-protein interactions within this signaling network .

What approaches can differentiate between p70S6K-dependent and independent phosphorylation of RPS6?

Differentiating between p70S6K-dependent and independent phosphorylation of RPS6 requires sophisticated experimental approaches. Researchers should employ site-specific phospho-antibodies as RPS6 undergoes phosphorylation on multiple serines (236, 235, 240, 244, 247) in a sequential order. Serines 235/236 can be phosphorylated by both p70S6K and p90RSK (downstream of the MAPK pathway), while serines 240/244/247 are exclusively phosphorylated by p70S6K. Using selective pathway inhibitors is crucial: rapamycin blocks mTOR/p70S6K activity, while MEK inhibitors (U0126, PD98059) block the MAPK/p90RSK pathway. Kinase assays with recombinant p70S6K and p90RSK using RPS6 as substrate, followed by phospho-specific antibody detection, can provide direct evidence of kinase-specific phosphorylation. For in vivo studies, comparing phosphorylation patterns in wild-type cells versus those expressing kinase-dead mutants of p70S6K or p90RSK can definitively attribute phosphorylation events to specific kinases .

How can RPS6 antibodies be utilized in RNA immunoprecipitation (RIP) assays?

RNA immunoprecipitation (RIP) assays using RPS6 antibodies can provide valuable insights into the specific mRNA populations associated with ribosomes under different cellular conditions. For optimal RIP experiments, crosslinking cells with formaldehyde prior to lysis preserves RNA-protein interactions. Using RPS6 antibodies (typically 0.5-4.0 μg per experiment) to immunoprecipitate RPS6-containing ribosomal complexes allows for the capture of actively translating mRNAs. Following immunoprecipitation, RNA can be extracted and analyzed via RT-qPCR for specific transcripts or RNA-seq for global analysis. This approach can identify transcripts preferentially translated under specific conditions (e.g., stress, growth factor stimulation) or in response to particular treatments. For differential analysis, comparing RIP results from control versus treated samples, or from cells expressing wild-type versus phosphorylation-deficient RPS6 mutants, can reveal how RPS6 phosphorylation status affects transcript selectivity .

How do species reactivity profiles differ among commercial RPS6 antibodies?

Commercial RPS6 antibodies show varying species reactivity profiles that researchers must consider when selecting reagents for cross-species studies. Many RPS6 antibodies demonstrate broad cross-reactivity due to the high sequence conservation of this protein across species. For instance, antibody 14823-1-AP has confirmed reactivity with human and mouse samples, while MAB5436 has verified reactivity with human, mouse, and rat samples. When working with less common research models, researchers should examine sequence homology in the immunogen region to predict potential cross-reactivity. For antibodies where cross-reactivity is predicted but not verified (such as zebrafish applications mentioned in citations for 14823-1-AP), validation experiments are essential before proceeding with full studies. These should include positive and negative controls alongside Western blotting to confirm appropriate molecular weight detection and specificity in the species of interest .

What are the critical considerations when selecting phospho-specific versus total RPS6 antibodies?

When selecting between phospho-specific and total RPS6 antibodies, researchers must consider several critical factors. Phospho-specific antibodies detect RPS6 only when phosphorylated at particular residues (e.g., serine 236), making them valuable for signaling pathway activation studies but unsuitable for measuring total protein expression. These antibodies require careful validation through peptide competition assays to confirm site-specificity. Total RPS6 antibodies recognize the protein regardless of phosphorylation status, making them essential for normalization when quantifying relative phosphorylation levels. For comprehensive signaling studies, researchers should employ both antibody types in parallel. Additionally, phospho-specific antibodies are more sensitive to sample preparation conditions; samples must be collected with phosphatase inhibitors and handled consistently to preserve phosphorylation status. Finally, when designing experiments to study complex phosphorylation patterns, consider that RPS6 undergoes phosphorylation on multiple serines in a sequential order (236→235→240→244→247), with different sites potentially having distinct functional implications .

Recommended Dilutions for RPS6 Antibodies by Application Type

Note: All dilutions should be optimized for specific experimental conditions .

Molecular Weight Detection Guide for RPS6 Antibodies

Note: Always include appropriate molecular weight markers and positive controls when interpreting Western blot results .